Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genoptix launches mutation analysis:

This article was originally published in Clinica

Executive Summary

Carlsbad, California-based diagnostic specialist Genoptix has launched a test for a genetic mutation that is associated with a greater risk of blood cancers. The product tests patients for the MPL W515 L/K mutation, which affects the thrombopoietin receptor and results in the continuous activation of certain intracellular molecular pathways. It is associated with two myeloproliferative disorders: idiopathic myelofibrosis and essential thrombocythaemia. MPL W515 L/K mutation analysis may be particularly useful for patients with suspected MPD that are negative for JAK2 mutations, Genoptix said. The company believes it will be the first haematology/oncology laboratory service provider to offer this test.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel